When did Amgen Inc file this 8-K?

Amgen Inc (AMGN) filed this Current Report (Form 8-K) with the SEC on May 20, 2026. The accession number assigned by EDGAR is 0001193125-26-232786.

What does an 8-K disclose?

Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).

What is the key takeaway from this filing?

All 12 director nominees were elected; executive compensation approved; auditors ratified; independent chair proposal rejected. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.

What Item codes does an 8-K cover?

An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.

Where can I find Amgen Inc's prior current reports on EDGAR?

The SEC EDGAR browser lists every 8-K Amgen Inc has filed under CIK 318154, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Boardroom Alpha

AMGN · Current Report (Form 8-K) · Filed May 20, 2026

Amgen Inc — Current Report (Form 8-K)

Form

8-K

Filed

May 20, 2026

Period

May 19, 2026

Ticker

AMGN

Accession

0001193125-26-232786

Amgen Inc on Boardroom Alpha View on SEC EDGAR

Boardroom Alpha · Filing insights

All 12 director nominees were elected; executive compensation approved; auditors ratified; independent chair proposal rejected.

About Amgen Inc

Market cap

$177.2B

1Y TSR

+18.8%

3Y TSR

+17.7%

Board grade

Sector

Healthcare

CEO

Robert A Bradway

Last annual meeting: May 19, 2026 · View full Amgen Inc profile →

8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 19, 2026

Amgen Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-37702	95-3540776
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One Amgen Center Drive
Thousand Oaks, California		91320-1799
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (805) 447-1000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.0001 par value	AMGN	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on May 19, 2026. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:

Item 1 - Election of Directors

Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company’s 2027 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.


Name	Votes For	Votes Against	Abstain	Broker Non-Votes
Dr. Wanda M. Austin	408,261,366	4,136,960	541,141	63,739,635
Mr. Robert A. Bradway	390,137,618	20,492,559	2,309,290	63,739,635
Dr. Michael V. Drake	407,302,029	4,797,875	839,563	63,739,635
Dr. Brian J. Druker	409,304,364	3,054,075	581,028	63,739,635
Mr. Robert A. Eckert	393,137,908	19,206,011	595,548	63,739,635
Mr. Greg C. Garland	390,923,223	21,425,903	590,341	63,739,635
Mr. Charles M. Holley, Jr.	402,699,984	9,642,231	597,252	63,739,635
Dr. S. Omar Ishrak	408,204,077	4,139,152	596,238	63,739,635
Dr. Tyler Jacks	400,237,518	12,117,252	584,697	63,739,635
Dr. Mary E. Klotman	407,732,503	4,398,737	808,227	63,739,635
Ms. Ellen J. Kullman	405,340,175	6,775,403	823,889	63,739,635
Ms. Amy E. Miles	406,709,817	5,385,886	843,764	63,739,635

Item 2 - Advisory Vote to Approve Our Executive Compensation

The advisory vote to approve our executive compensation was approved.


For:	399,315,381
Against:	11,987,682
Abstain:	1,636,404
Broker Non-Votes:	63,739,635

Item 3 - Ratification of Selection of Independent Registered Public Accountants

Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2026. No Broker Non-Votes resulted from the vote on this proposal.


For:	447,904,443
Against:	28,209,748
Abstain:	564,911

Item 4 - Stockholder Proposal to Require an Independent Board Chairman

The stockholder proposal to require an independent board chairman was not approved.


For:	72,902,413
Against:	338,465,655
Abstain:	1,571,399
Broker Non-Votes:	63,739,635

No other matters were submitted for stockholder action.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			AMGEN INC.

Date:	May 20, 2026	By:	/s/ Jonathan P. Graham
			Name: Jonathan P. Graham
			Title: Executive Vice President and General Counsel and Secretary

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

See Filings Intelligence Schedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Amgen Inc (AMGN)

8-KCurrent Report
May 19, 2026
10-QQuarterly Report
May 1, 2026
8-KCurrent Report
Apr 30, 2026
8-KCurrent Report
Apr 22, 2026
DEFA14AAdditional Proxy Materials
Apr 21, 2026
DEFA14AAdditional Proxy Materials
Apr 15, 2026
DEFA14AAdditional Proxy Materials
Apr 7, 2026
DEF 14AProxy Statement
Apr 7, 2026
8-KCurrent Report
Feb 19, 2026
10-KAnnual Report
Feb 13, 2026
8-KCurrent Report
Feb 3, 2026
8-KCurrent Report
Jan 30, 2026

Continue researching

Reference

Frequently asked questions

When did Amgen Inc file this 8-K?: Amgen Inc (AMGN) filed this Current Report (Form 8-K) with the SEC on May 20, 2026. The accession number assigned by EDGAR is 0001193125-26-232786.
What does an 8-K disclose?: Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?: All 12 director nominees were elected; executive compensation approved; auditors ratified; independent chair proposal rejected. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?: An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Amgen Inc's prior current reports on EDGAR?: The SEC EDGAR browser lists every 8-K Amgen Inc has filed under CIK 318154, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer